What the research found
This is a self-experiment, not controlled research. The author is testing two separate interventions on himself over approximately two months.
For the first experiment, he's injecting a peptide blend containing BPC-157, TB-500, KPV, and GHK-Cu directly into the area around his distal bicep tendon (where the bicep attaches at the elbow) to manage tendonitis that developed from training. He initially used all four peptides at 400 mcg each daily, but switched to a two-peptide formulation (BPC-157 and TB-500 only) after one month due to skin irritation from the GHK-Cu. After one month of the full blend, he reports no subjective improvement in the tendon soreness during pulling movements or daily activities, though he's continuing the experiment to reach the two-month mark based on anecdotal reports suggesting slower timelines for tendon healing.
For the second experiment, he's using a tirzepatide/retatrutide blend (GLP-1 receptor agonists) to suppress appetite while maintaining a 1500–1800 calorie daily deficit and increased training volume. Over approximately one month, he lost 9 pounds (179 to 170 lbs) with the goal of reaching 160 lbs to achieve visible abdominal muscle definition. He notes continued strength gains despite the deficit but acknowledges that visible ab definition may also require additional direct abdominal muscle development, not just fat loss.
Why it matters for you
The tendon repair experiment touches on a common frustration for strength athletes: managing overuse injuries while staying active. If you've dealt with tendonitis or joint irritation, you've likely faced the trade-off between rest and deconditioning. Local peptide injection is appealing in theory—delivering potentially pro-repair compounds directly to damaged tissue—but this self-report reinforces that results are neither immediate nor guaranteed, and even anecdotal support suggests waiting several months for meaningful change. The skin reaction to GHK-Cu is also a practical consideration if you're considering similar local injections.
The second experiment is more straightforward: it's a calorie deficit amplified by appetite suppression. GLP-1 drugs like tirzepatide make a sustained 1500-calorie intake feasible for many people, removing the constant hunger that typically derails cutting phases. The author's ability to maintain strength and training volume during this deficit is notable—though he's still in the early, relatively easy phase of fat loss (the first 5 lbs came quickly; progress since has slowed). If you track body composition or use these medications, this honest account of the grinding final stages of a cut—where you're eating very little and training hard but seeing minimal weekly change—is realistic.
Caveats
- N=1, uncontrolled: These are anecdotes from one person with no comparison group or blinding. Individual variation in healing, metabolism, and response to peptides is enormous.
- Confounding variables: The tendon injury involved training modifications (cessation of curls, reduced bicep work) that likely affect outcomes independent of peptide use. The cutting experiment combines medication, calorie deficit, and increased training volume, making it impossible to isolate the effect of any single factor.
- Short follow-up: One month is genuinely too early to evaluate tendon repair claims. The author himself acknowledges this and plans to continue.
- Self-reported outcomes: No imaging, no objective strength testing of the injured tendon, no biomarkers. Symptom perception can shift for reasons unrelated to treatment.
- Commercial context: The source is a vendor, creating inherent bias toward promoting peptide use regardless of outcome.